Back to Search
Start Over
Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma
- Source :
- British journal of haematology. 182(5)
- Publication Year :
- 2017
- Subjects :
- 0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
Time Factors
Risk Assessment
Maintenance Chemotherapy
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
nodular lymphocyte-predominant Hodgkin lymphoma
Medicine
Humans
Lymphocytes
Aged
business.industry
Remission Induction
risk-adapted therapy
rituximab
Histiocytes
Hematology
Middle Aged
Prognosis
Hodgkin Disease
Survival Analysis
030104 developmental biology
Treatment Outcome
Nodular Lymphocyte Predominant Hodgkin Lymphoma
030220 oncology & carcinogenesis
Treatment strategy
Rituximab
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 13652141
- Volume :
- 182
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- British journal of haematology
- Accession number :
- edsair.doi.dedup.....722d26076f7948e56bba24621e0cd4a9